Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study

What Was Tested

This observational study looks at Octreotide and Somatostatin.

The researchers aimed to explore the relationship between responsiveness to SRLs relative to somatostatin (SST)2A and 5 receptor expression, adenoma granularity, and T2-weighted magnetic resonance imaging (MRI) signal intensity (T2WSI).

Why It Was Studied

Somatostatin receptor ligands (SRLs) are the cornerstone medical treatments for acromegaly; however, many patients remain unresponsive to SRLs.

Well-established predictive markers of response are needed.

Who Took Part

Forty-nine naïve patients (ie, patients without preoperative SRL treatment) with active acromegaly following surgery were treated with octreotide (group 1; n = 47), or pasireotide if uncontrolled under first-generation SRLs (group 2; n = 9).

Biochemical measurements, immunohistochemistry studies, and MRI readings were centralized.

How the Study Was Run

In design terms this was a multicenter study.

More than one site took part, so the participants came from several places.

The researchers conducted a multicentric, prospective, observational cohort study, in France.

Data were collected at baseline and months 3 and 6.

What Was Measured

The subject headings attached to it are Acromegaly, Growth Hormone-Secreting Pituitary Adenoma, Receptors, Somatostatin, Octreotide, Insulin-Like Growth Factor I, Ligands and Adenoma.

Author keywords: growth hormone (GH), insulin growth factor-I (IGF-I) and somatostatin receptor.

What This Means in Plain Language

The paper is a multicenter study of Octreotide and Somatostatin.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.